<DOC>
	<DOCNO>NCT01227408</DOCNO>
	<brief_summary>The investigator propose conduct clinical trial neoadjuvant treatment utilize chemotherapy formulation favorable toxicity profile : weekly doxorubicin , PPX capecitabine . It expect combination least maintain efficacy traditional chemotherapy regimen associate less toxicity , particularly nausea , vomit alopecia . In order accomplish investigator design chemotherapy regimen whose component ( administration schedule ) associate minimal alopecia also consider low emetogenic potential . In attempt improve efficacy regimen investigator plan study alternate schedule cyclophosphamide methotrexate administration ( metronomic chemotherapy ) appear inhibit angiogenesis therefore enhance activity conventional cytotoxic chemotherapy administer concurrently . In trial investigator aim determine clinical pathologic response rate 12 week doxorubicin follow 4 cycle PPX capecitabine . Metronomic chemotherapy cyclophosphamide methotrexate administer 24 week chemotherapy .</brief_summary>
	<brief_title>Neoadjuvant Doxorubicin , Polyglutamate Paclitaxel , Capecitabine Metronomic Chemotherapy Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>SWOG performance status 02 Projected life expectancy least 3 month Female age 18 year Provision inform consent prior studyrelated procedure . Hormone receptor positive negative tumor Her 2 neu negative tumor Negative pregnancy test woman childbearing potential Patients must agree use form contraception study initiation duration participation study . Sexually active male must also use reliable appropriate method contraception . Postmenopausal woman must amenorrheic least 12 month consider nonchildbearing potential . ANC &gt; 1500 , Platelet count &gt; 100,000 , Hemoglobin &gt; 9.0 Serum creatinine &lt; 1.5 mg/dl Hepatic function : Patients must adequate liver function : AST ALT &lt; 2.5 X upper limit normal ( ULN ) , alkaline phosphatase &lt; 2.5 X upper limit normal . Serum Bilirubin &lt; 1.5 mg Peripheral neuropathy grade 01 No concomitant therapy direct cancer allow . Serum bilirubin &gt; 1.5 upper limit reference range ( ULRR ) Serum creatinine &gt; 1.5 Prior therapy tumor . Clinical Congestive Heart Failure Women currently pregnant breast feeding . Receipt investigational agent within 30 day prior commence study treatment Prior radiation must include â‰¥ 30 % major bone marrow contain area ( pelvis , lumbar spine ) No prior malignancy allow except follow : adequately treat basal cell squamous cell skin cancer , situ cervical cancer , lobular carcinoma insitu breast ( LCIS ) , cancer patient diseasefree 5 year . Patients prior invasive breast cancer ductal carcinoma insitu ( DCIS ) eligible disease free 5 year receive prior treatment doxorubicin and/or taxane .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Patients confirm breast cancer neoadjuvant chemotherapy</keyword>
</DOC>